These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 32587099

  • 21. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
    Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions.
    Bardhi K, Coates S, Chen G, Lazarus P.
    Pharmaceutics; 2024 Feb 07; 16(2):. PubMed ID: 38399297
    [Abstract] [Full Text] [Related]

  • 25. Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.
    Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS.
    Psychopharmacology (Berl); 2011 Nov 07; 218(2):443-57. PubMed ID: 21667074
    [Abstract] [Full Text] [Related]

  • 26. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
    Mitchell VA, Harley J, Casey SL, Vaughan AC, Winters BL, Vaughan CW.
    Neuropharmacology; 2021 May 15; 189():108529. PubMed ID: 33741405
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ9-Tetrahydrocannabinol Without Improving Its Analgesic Properties.
    Gorbenko AA, Heuberger JAAC, Klumpers LE, de Kam ML, Strugala PK, de Visser SJ, Groeneveld GJ.
    Clin Pharmacol Ther; 2024 Nov 15; 116(5):1289-1303. PubMed ID: 39054656
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
    Nasrin S, Watson CJW, Bardhi K, Fort G, Chen G, Lazarus P.
    Drug Metab Dispos; 2021 Dec 15; 49(12):1081-1089. PubMed ID: 34493601
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
    Yamaori S, Kushihara M, Yamamoto I, Watanabe K.
    Biochem Pharmacol; 2010 Jun 01; 79(11):1691-8. PubMed ID: 20117100
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.
    Coates S, Bardhi K, Lazarus P.
    Pharmaceutics; 2024 Mar 18; 16(3):. PubMed ID: 38543313
    [Abstract] [Full Text] [Related]

  • 34. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism.
    Xiong W, Koo BN, Morton R, Zhang L.
    Neuroscience; 2011 Jun 16; 184():28-37. PubMed ID: 21477640
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
    Wolowich WR, Greif R, Kleine-Brueggeney M, Bernhard W, Theiler L.
    Eur J Drug Metab Pharmacokinet; 2019 Oct 16; 44(5):691-711. PubMed ID: 31114948
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The pharmacokinetics and the pharmacodynamics of cannabinoids.
    Lucas CJ, Galettis P, Schneider J.
    Br J Clin Pharmacol; 2018 Nov 16; 84(11):2477-2482. PubMed ID: 30001569
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.